Kazia Therapeutics (KZIA) Income from Non-Controlling Interests (2013 - 2016)
Kazia Therapeutics' (KZIA) quarterly Income from Non-Controlling Interests came in at $69764.7 in Q4 2016, down 41.95% YoY from $120188.3 in Q1 2016, and little changed on a QoQ basis from $69443.3 in Q2 2016.
Kazia Therapeutics (KZIA) Income from Non-Controlling Interests (2013 - 2016) Analysis & Trends
Kazia Therapeutics (KZIA) has 4 years of Income from Non-Controlling Interests data on file, last reported at $69764.7 in Q4 2016.
- Quarterly Income from Non-Controlling Interests fell 41.95% year-over-year to $69764.7 in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $345792.8 (down 100.0% YoY) and the FY2016 annual result came in at -$69964.5, up 45.76% from the prior year.
- Income from Non-Controlling Interests held at $69764.7 in Q4 2016, from $69443.3 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $14.6 billion in Q4 2013 to a low of $69443.3 in Q2 2016.
- A 4-year average of $2.9 billion and a median of $86396.5 in 2014 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2014 — Income from Non-Controlling Interests plunged 100.0% — and 2015, when it jumped 39.11%.
- Tracing KZIA's Income from Non-Controlling Interests over 4 years: stood at $14.6 billion in 2013, then sank by 100.0% to $86396.5 in 2014, then jumped by 39.11% to $120188.3 in 2015, then slumped by 41.95% to $69764.7 in 2016.
- The last three Income from Non-Controlling Interests figures came in at $69764.7 (Q4 2016), $69443.3 (Q2 2016), and $120188.3 (Q4 2015), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 63.60 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Kazia Therapeutics | 4.22 Bn | 4.22 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 69,764.73 |
| Jun 30, 2016 | 69,443.32 |
| Dec 31, 2015 | 120,188.25 |
| Dec 31, 2014 | 86,396.46 |
| Dec 31, 2013 | 14.64 Bn |